The median survival of patients showing neither STAT1 nor STAT3 activity (nuclear) in their tumor specimens was at least 33 months shorter in comparison to patients with tumor related activation of STAT1, STAT3 or both proteins (Figure 1b). This evidence concerns the gene STAT1 and neoplasm.